Madoz-Gúrpide J - Search Results

1

The molecular pathogenesis of Ewing's sarcoma.

Mackintosh C, Madoz-Gúrpide J, Ordóñez JL, Osuna D, Herrero-Martín D. Mackintosh C, et al. Cancer Biol Ther. 2010 May 1;9(9):655-67. doi: 10.4161/cbt.9.9.11511. Epub 2010 May 12. Cancer Biol Ther. 2010. PMID: 20215864 Review.

2

Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.

Herrero-Martín D, Osuna D, Ordóñez JL, Sevillano V, Martins AS, Mackintosh C, Campos M, Madoz-Gúrpide J, Otero-Motta AP, Caballero G, Amaral AT, Wai DH, Braun Y, Eisenacher M, Schaefer KL, Poremba C, de Alava E. Herrero-Martín D, et al. Br J Cancer. 2009 Jul 7;101(1):80-90. doi: 10.1038/sj.bjc.6605104. Epub 2009 Jun 2. Br J Cancer. 2009. PMID: 19491900 Free PMC article.

3

A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.

Martins AS, Ordoñez JL, García-Sánchez A, Herrero D, Sevillano V, Osuna D, Mackintosh C, Caballero G, Otero AP, Poremba C, Madoz-Gúrpide J, de Alava E. Martins AS, et al. Cancer Res. 2008 Aug 1;68(15):6260-70. doi: 10.1158/0008-5472.CAN-07-3074. Cancer Res. 2008. PMID: 18676850

4

Advances in Ewing's sarcoma research: where are we now and what lies ahead?

Ordóñez JL, Osuna D, Herrero D, de Alava E, Madoz-Gúrpide J. Ordóñez JL, et al. Cancer Res. 2009 Sep 15;69(18):7140-50. doi: 10.1158/0008-5472.CAN-08-4041. Epub 2009 Sep 8. Cancer Res. 2009. PMID: 19738075 Review.

5

Mining sarcomas by proteomics approaches: Ewing sarcoma on the spotlight.

Mackintosh C, Madoz-Gúrpide J. Mackintosh C, et al. Recent Pat Biotechnol. 2013 Aug;7(2):98-111. doi: 10.2174/18722083113079990004. Recent Pat Biotechnol. 2013. PMID: 23848272 Review.

6

Targeting sarcomas: therapeutic targets and their rational.

Ordóñez JL, Martins AS, Osuna D, Madoz-Gúrpide J, de Alava E. Ordóñez JL, et al. Semin Diagn Pathol. 2008 Nov;25(4):304-16. doi: 10.1053/j.semdp.2008.07.005. Semin Diagn Pathol. 2008. PMID: 19013896 Review.

7

A proteomics analysis of cell signaling alterations in colorectal cancer.

Madoz-Gúrpide J, Cañamero M, Sanchez L, Solano J, Alfonso P, Casal JI. Madoz-Gúrpide J, et al. Mol Cell Proteomics. 2007 Dec;6(12):2150-64. doi: 10.1074/mcp.M700006-MCP200. Epub 2007 Sep 11. Mol Cell Proteomics. 2007. PMID: 17848589 Free article.

8

Other targetable sarcomas.

Pires de Camargo V, van de Rijn M, Maestro R, de Alava E, Madoz-Gúrpide J, Pilotti S, von Mehren M, Pedeutour F, Maki RG, Rutkowski P, Thomas DM. Pires de Camargo V, et al. Semin Oncol. 2009 Aug;36(4):358-71. doi: 10.1053/j.seminoncol.2009.06.008. Semin Oncol. 2009. PMID: 19664496 Review.

9

Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines.

Zazo S, González-Alonso P, Martín-Aparicio E, Chamizo C, Cristóbal I, Arpí O, Rovira A, Albanell J, Eroles P, Lluch A, Madoz-Gúrpide J, Rojo F. Zazo S, et al. Am J Cancer Res. 2016 Nov 1;6(11):2661-2678. eCollection 2016. Am J Cancer Res. 2016. PMID: 27904779 Free PMC article.

10

Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.

Guardia C, Bianchini G, Arpí-LLucià O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero JC, Soria-Jiménez L, Sabbaghi M, Peña R, Madoz-Gúrpide J, Lloveras B, Lluch A, Eroles P, Arribas J, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J. Guardia C, et al. Clin Cancer Res. 2021 Sep 15;27(18):5096-5108. doi: 10.1158/1078-0432.CCR-20-2915. Epub 2021 Aug 12. Clin Cancer Res. 2021. PMID: 34385295

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

77 results

Search Page